Visszavonva2. fázis
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
A legfontosabb adatok
- Ki végzi
- Johns Hopkins University
- Hol
- Baltimore (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 2. fázis
- Kezdés
- 2027. ápr.
- Várható befejezés
- 2028. júl.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Psilocybin
- A regiszteradat frissítve
- 2026. február 23.
- Miért állt le
- This study was de-prioritized in favor of the similar BIPOD-Out protocol due to a combination of practical considerations and expense. There are currently no plans to initiate this protocol.
Ki vehet részt
- Életkor
- 21 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Age 21-70 years
- Have given written informed consent
- Meet diagnostic criteria for OUD
- No antidepressant medications for approximately 5 half-lives prior to enrollment
- Not currently taking methadone, buprenorphine or naltrexone
- Urine toxicology positive for an opioid
- Has access to stable housing
- Can read, write, and speak English fluently
- Be judged by study team clinicians to be at low risk for suicidality
- Have limited recent use of classic psychedelics (no use in the past year)
- Expresses a desire for sustained recovery from disordered opioid use
Ki nem vehet részt
- Currently taking on a daily basis any medications (including herbal substances and supplements) with a central nervous system effect on serotonin, including serotonin-reuptake inhibitors and monoamine oxidase inhibitors; o For individuals who have intermittent or as needed use of such medications, psilocybin sessions will not be conducted until at least 5 half-lives of the agent have elapsed after the last dose
- Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or medicines such as phenytoin, regorafenib, eltrombopag
- Currently taking buprenorphine, methadone, or naltrexone
- Unable or unwilling to discontinue acid-reducing agents or major metabolizing enzyme inhibitors for 5-half lives prior to the experimental dosing session
- Cardiovascular conditions: hypertension with resting blood pressure systolic >139 or diastolic >89, angina, heart rate > 99, a clinically significant electrocardiogram abnormality (e.g., atrial fibrillation), Transient Ischemic Attack or Stroke in the last 6 months, peripheral or pulmonary vascular disease, cardiac valvulopathy
- Epilepsy
- Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
- Have a seizure disorder, multiple sclerosis, history of significant head trauma, nervous system tumor, movement disorders or any neurodegenerative condition
- Morbidly obese (>100 pounds above ideal body weight, or Body Mass Index (BMI) >=40, or BMI >=35 with high blood pressure or diabetes)
- Allergic to buprenorphine or hydromorphone
- Current or past history of meeting diagnostic criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), Bipolar I or II Disorder or Major Depression with psychotic features
- Have a first or second degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or bipolar I or II disorder
- For blood samples, the following lab values will be exclusionary: transaminases greater than x2 the upper limit of normal lab reference range, hemoglobin less than 11 g/d, and creatinine clearance < 40 ml/min; Psychiatric Exclusion Criteria:
- General medical exclusion criteria:
- Women who are pregnant, nursing, or not practicing an effective means of birth control
- Body weight < 45 kilograms
- Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal
Helyszínek itt: Egyesült Államok
- Johns Hopkins UniversityBaltimore, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.
A vizsgálat 2 csoportja
- High-dose psilocybin + buprenorphineA vizsgált kezelés
High-dose psilocybin (30 mg) session following standard-of-care buprenorphine induction
Kezelés: Psilocybin
- Very low-dose psilocybin + buprenorphineMár használt kezelés, összehasonlításként
Very low dose psilocybin session (1 mg) following standard-of-care buprenorphine induction
Kezelés: Psilocybin
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial
- A regiszteradat frissítve
- 2026. február 23.